Somatostatin Receptor Imaging in Cardiac Sarcoidosis

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02812849

Enrollment

Registered

2016-06-24

Start date

2016-06-30

Completion date

2020-02-27

Last updated

2020-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Sarcoidosis

Brief summary

The purpose of the trial is to determine the accuracy of Cu-64 labelled DOTATATE for diagnosing cardiac sarcoidosis using PET/CT or PET/MRI.

Interventions

DRUGCu-64 DOTATATE

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Group A: Suspected cardiac sarcoidosis Group B: Known cardiac sarcoidosis, clinical follow-up Group C: Myocarditis or dilated cardiomyopathy (Non-cardiac sarcoidosis)

Exclusion criteria

Infection Pregnancy Severe claustrophobia Weight \>140 kg

Design outcomes

Primary

Measure	Time frame
Sensitivity to detect cardiac sarcoidosis	1 day at PET/CT examination
Specificity to detect cardiac sarcoidosis	1 day at PET/CT examination

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026